UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d) of the
Securities Exchange Act of 1934
Date of
report (Date of earliest event reported): November 29, 2017
|
CORMEDIX
INC.
|
||
|
(Exact
Name of Registrant as Specified in Charter)
|
||
|
|
|
|
|
Delaware
|
001-34673
|
20-5894890
|
|
(State
or Other Jurisdiction
of
Incorporation)
|
(Commission
File
Number)
|
(IRS
Employer
Identification
No.)
|
|
|
|
|
|
400
Connell Drive, Suite 5000, Berkeley Heights, NJ
|
07922
|
|
|
(Address
of Principal Executive Offices)
|
(Zip
Code)
|
|
Registrant’s
Telephone Number, Including Area Code: (908) 517-9500
|
|
|
(Former
Name or Former Address, If Changed Since Last Report)
|
Check
the appropriate box below if the Form 8-K filing is intended to
simultaneously satisfy the filing obligation of the registrant
under any of the following provisions (see General Instruction A.2.
below):
☐
Written
communications pursuant to Rule 425 under the Securities Act (17
CFR 230.425)
☐
Soliciting material
pursuant to Rule 14a-12 under the Exchange Act (17 CFR
240.14a-12)
☐
Pre-commencement
communications pursuant to Rule 14d-2(b) under the Exchange Act (17
CFR 240.14d-2(b))
☐
Pre-commencement
communications pursuant to Rule 13e-4(c) under the Exchange Act (17
CFR 240.13e-4(c))
Indicate
by check mark whether the registrant is an emerging growth company
as defined in Rule 405 of the Securities Act of 1933 (§230.405
of this chapter) or Rule 12b-2 of the Securities Exchange Act of
1934 (§240.12b-2 of this chapter).
Emerging
growth company ☐
If an
emerging growth company, indicate by check mark if the registrant
has elected not to use the extended transition period for complying
with any new or revised financial accounting standards provided
pursuant to Section 13(a) of the Exchange Act. ☐
Item 5.02. Departure of Directors or Principal Offciers; Election
of Directors; Appointment of Principal Officers.
On
November 29, 2017, our Board of Directors approved hiring Dr. Gary
Gelbfish, one of our directors, as a consultant to assist in our
planned interim analysis for the ongoing LOCK IT 100 clinical trial
for Neutrolin. For his services, we will pay Dr. Gelbfish $800.00
per hour and will pay him for services rendered since November 10,
2017. As a result of this arrangement, Dr. Gelbfish has resigned
from the Audit Committee and the Board has appointed Myron Kaplan
to replace him on the Audit Committee.
Pursuant to the
requirements of the Securities Exchange Act of 1934, the registrant
has duly caused this report to be signed on its behalf by the
undersigned hereunto duly authorized.
|
|
CORMEDIX
INC.
|
|
|
|
|
|
|
|
|
Date: December 5,
2017
|
By:
|
/s/
Robert
W. Cook
|
|
|
|
Name:
|
Robert W.
Cook
|
|
|
|
Title:
|
Chief Financial
Officer
|
|